Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:ageRange |
18 years and older
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:completedIn |
May 2023
|
| gptkbp:condition |
gptkb:COVID-19
|
| gptkbp:enrollment |
44000
|
| https://www.w3.org/2000/01/rdf-schema#label |
NCT04601051
|
| gptkbp:intervention |
gptkb:Placebo
gptkb:Ad26.COV2.S Parallel Assignment |
| gptkbp:location |
gptkb:Brazil
gptkb:South_Africa gptkb:United_States |
| gptkbp:mask |
Double
|
| gptkbp:officialName |
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older
|
| gptkbp:purpose |
Prevention
|
| gptkbp:recognizedBy |
gptkb:NCT04601051
|
| gptkbp:result |
Efficacy of Ad26.COV2.S in preventing moderate to severe/critical COVID-19
|
| gptkbp:sponsor |
gptkb:Janssen_Vaccines_&_Prevention_B.V.
|
| gptkbp:startDate |
September 2020
|
| gptkbp:status |
Completed
|
| gptkbp:studyType |
Interventional
|
| gptkbp:bfsParent |
gptkb:NTLA-2001
|
| gptkbp:bfsLayer |
6
|